vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and INTRUSION INC (INTZ). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.5M, roughly 1.7× INTRUSION INC). INTRUSION INC runs the higher net margin — -190.7% vs -265.2%, a 74.5% gap on every dollar of revenue. Over the past eight quarters, INTRUSION INC's revenue compounded faster (14.4% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
INTRUSION INCINTZEarnings & Financial Report
Intrusion Inc. is a cybersecurity company based in Plano, Texas. It provides cybersecurity solutions, including network intrusion detection and prevention systems.
BOLT vs INTZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.5M |
| Net Profit | $-6.6M | $-2.8M |
| Gross Margin | — | 74.3% |
| Operating Margin | -283.4% | -192.4% |
| Net Margin | -265.2% | -190.7% |
| Revenue YoY | — | -11.6% |
| Net Profit YoY | 58.4% | -44.4% |
| EPS (diluted) | $-9.38 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.5M | ||
| Q3 25 | $2.2M | $2.0M | ||
| Q2 25 | $1.8M | $1.9M | ||
| Q1 25 | $1.2M | $1.8M | ||
| Q4 24 | $0 | $1.7M | ||
| Q3 24 | $1.1M | $1.5M | ||
| Q2 24 | $1.3M | $1.5M | ||
| Q1 24 | $5.3M | $1.1M |
| Q4 25 | $-6.6M | $-2.8M | ||
| Q3 25 | $-7.1M | $-2.1M | ||
| Q2 25 | $-8.6M | $-2.0M | ||
| Q1 25 | $-11.0M | $-2.1M | ||
| Q4 24 | $-15.9M | $-2.0M | ||
| Q3 24 | $-15.2M | $-2.0M | ||
| Q2 24 | $-21.2M | $-2.1M | ||
| Q1 24 | $-10.8M | $-1.7M |
| Q4 25 | — | 74.3% | ||
| Q3 25 | — | 76.6% | ||
| Q2 25 | — | 76.4% | ||
| Q1 25 | — | 75.7% | ||
| Q4 24 | — | 74.9% | ||
| Q3 24 | — | 77.1% | ||
| Q2 24 | — | 76.0% | ||
| Q1 24 | — | 80.0% |
| Q4 25 | -283.4% | -192.4% | ||
| Q3 25 | -355.1% | -108.6% | ||
| Q2 25 | -510.5% | -111.4% | ||
| Q1 25 | -991.4% | -117.9% | ||
| Q4 24 | — | -113.5% | ||
| Q3 24 | -1441.1% | -135.5% | ||
| Q2 24 | -1772.3% | -139.2% | ||
| Q1 24 | -324.1% | -218.6% |
| Q4 25 | -265.2% | -190.7% | ||
| Q3 25 | -329.4% | -106.5% | ||
| Q2 25 | -474.6% | -109.0% | ||
| Q1 25 | -903.4% | -118.2% | ||
| Q4 24 | — | -116.8% | ||
| Q3 24 | -1330.1% | -136.3% | ||
| Q2 24 | -1662.4% | -141.6% | ||
| Q1 24 | -205.0% | -151.7% |
| Q4 25 | $-9.38 | $-0.15 | ||
| Q3 25 | $-3.72 | $-0.10 | ||
| Q2 25 | $-4.46 | $-0.10 | ||
| Q1 25 | $-0.29 | $-0.11 | ||
| Q4 24 | $-13.73 | $0.19 | ||
| Q3 24 | $-7.93 | $-0.35 | ||
| Q2 24 | $-11.12 | $-0.53 | ||
| Q1 24 | $-0.28 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $3.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $7.3M |
| Total Assets | $56.7M | $10.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $3.6M | ||
| Q3 25 | $31.9M | $4.5M | ||
| Q2 25 | $34.8M | $8.4M | ||
| Q1 25 | $38.8M | $10.7M | ||
| Q4 24 | $47.3M | $4.9M | ||
| Q3 24 | $53.8M | $1.1M | ||
| Q2 24 | $73.7M | $1.5M | ||
| Q1 24 | $91.3M | $122.0K |
| Q4 25 | $26.5M | $7.3M | ||
| Q3 25 | $32.1M | $9.8M | ||
| Q2 25 | $38.8M | $11.6M | ||
| Q1 25 | $46.8M | $13.4M | ||
| Q4 24 | $57.2M | $6.3M | ||
| Q3 24 | $72.0M | $2.6M | ||
| Q2 24 | $85.9M | $2.9M | ||
| Q1 24 | $104.2M | $-1.2M |
| Q4 25 | $56.7M | $10.4M | ||
| Q3 25 | $65.1M | $13.7M | ||
| Q2 25 | $75.5M | $16.4M | ||
| Q1 25 | $85.9M | $18.0M | ||
| Q4 24 | $99.6M | $11.5M | ||
| Q3 24 | $109.3M | $7.4M | ||
| Q2 24 | $124.2M | $7.5M | ||
| Q1 24 | $142.9M | $5.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-531.0K |
| Free Cash FlowOCF − Capex | — | $-549.0K |
| FCF MarginFCF / Revenue | — | -37.1% |
| Capex IntensityCapex / Revenue | — | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-531.0K | ||
| Q3 25 | $-9.7M | $-3.0M | ||
| Q2 25 | $-9.6M | $-1.6M | ||
| Q1 25 | $-13.4M | $-1.7M | ||
| Q4 24 | $-14.4M | $-178.0K | ||
| Q3 24 | $-14.0M | $-2.1M | ||
| Q2 24 | $-16.1M | $-2.9M | ||
| Q1 24 | $-16.8M | $-1.1M |
| Q4 25 | — | $-549.0K | ||
| Q3 25 | — | $-3.0M | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-645.0K | ||
| Q3 24 | $-14.0M | $-2.1M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $-1.2M |
| Q4 25 | — | -37.1% | ||
| Q3 25 | — | -153.2% | ||
| Q2 25 | — | -101.1% | ||
| Q1 25 | — | -117.3% | ||
| Q4 24 | — | -38.5% | ||
| Q3 24 | -1227.6% | -140.4% | ||
| Q2 24 | — | -202.3% | ||
| Q1 24 | — | -104.2% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 17.8% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | 3.6% | 2.2% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 5.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
